[1] Lok AS, McMahon BJ, Brown RS Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology, 2016, 63: 284-306.
[2] Kowdley KV, Wang CC, Welch S, et al. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology, 2012, 56: 422-433.
[3] Eun LH Jr, Lee SH, Kim TN, et al. The effect of lamivudine and adefovir dipivoxil on preventing hepatocellular carcinoma in HBV-related liver cirrhosis. Hepatology, 2007, 46: 664A-665A.
[4] Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths inchronic hepatitis B patients with liver cirrhosis. Hepatology, 2013, 58 :1537-1547.
[5] Garg H, Sarin SK, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology, 2011, 53 : 774-780.
[6] Wang H, Ji YY, Yao GB, et al. Two years efficiency of lamivudine and adefovir dipivoxil combined therapy in chronic hepatitis B patients. Eur Rev Med Pharmacol Sci, 2013, 17: 636-643.
[7] Lim YS, Han S, Heo NY, et al. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology, 2014, 147:152-161.
[8] Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology, 2011, 54: 91-100.
[9] Hsu YC, Mo LR, Chang CY, et al. Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation. Antivir Ther, 2012, 17: 605-612.
[10] Chan HL, Chan CK, Hui AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levelsof hepatitis B virus DNA. Gastroenterology, 2014, 146: 1240-1248.
[11] Lu J, Zhang S, Liu Y, et al. Effect of peginterferon alpha-2a combined with adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA. Liver Int, 2015, 35:1692-1699.
[12] Chaung KT, Ha NB, Trinh HN, et al. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol, 2012, 46: 865-870.
[13] Fung J, Lai CL, Tanaka Y, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol, 2009, 104:1940-1947.
[14] Sinn DH, Lee J, Goo J, et al. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology, 2015, 62:694-701.
[15] Terrault N, Bzowej N, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016, 63: 261-283.
[16] Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology, 2006, 130: 678-686.
[17] Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 2006, 295:65-73.
[18] Iloeje UH, Yang HI, Jen CL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol, 2007, 5: 921-931. |
